Thyroid cancer therapy with I-131. Malignant neoplasms of thyroid and other endocrine glands
Conditions
Interventions
Intervention 1: Intervention group(1): using sugar-free chewing gum from the first day of treatment. Intervention 2: Intervention group(2): using sugar-free chewing gum from the second day of treatm
Prevention
Intervention group(1): using sugar-free chewing gum from the first day of treatment.
Intervention group(2): using sugar-free chewing gum from the second day of treatment
Control Group: Do not use chewing gum
Sponsors
Shiraz university of medical science, Vice chancellor for research
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1- Patients older than 20 years for whom thyroidectomy has been performed for 4-6 weeks prior to initiation of the study due to differenciated thyroid cancer and are referred to Namazi Hospital Center of Nuclear Medicine for ablative radioactive iodine -131 therapy; 2- Patients who have received low-iodine diet for two weeks; 3- Patients must be at hypothyroid state at the time of the study; 4- Patients should have signed the informed consent form and should give permission for their participation in the study; Exclusion Criteria: 1- Any positive history of previous salivary gland diseases; 2- Any positive history of collagen tissue diseases; 3- Positive history of Phenylketonuria; 4- Positive history of using diuretics, Antihistamines, Antidepressants or Anticholinergic medications; 5- Positive history of previously receiving Radiotherapy at Head & Neck region; 6- Positive history of previous treatment with radioiodine ( 131I ); 7- Difficulty in taking large amount of fluid;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radioiodine absorbed dose. Timepoint: 5 time points : At 2, 5, 13, 24 & 48 hours after receiving Radioiodine. Method of measurement: Radioiodine absorbed dose will be measured by scintigraphy and the amounts measured will be interpreted by MIRD Schema software. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of Sialadenitis and Xerostomia in under study patients. Timepoint: Attime points: 1 week after initial admission period then monthly follow ups till 6 months. Method of measurement: By making phone calls at chosen time points and collecting subjective data about patients’ symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNuclear medicine and molecular imaging research center
Shiraz university of medical science
Outcome results
None listed